Novel therapies and innovation for systemic sclerosis skin ulceration
- PMID: 36609122
- PMCID: PMC11671032
- DOI: 10.1016/j.berh.2022.101813
Novel therapies and innovation for systemic sclerosis skin ulceration
Abstract
Skin ulceration is an important cause of morbidity in systemic sclerosis and can occur at anytime during disease progression. Incident disease cohorts are important for understanding whether skin ulceration represents active vasculopathy versus resultant damage. Biomarkers for skin ulcer pathogenesis, both serum and imaging, are under investigation to elucidate the functional consequences of the structural abnormalities. Novel therapeutics for the treatment of vasculopathy benefit from reliable biomarkers able to predict the disease evolution remains an important unmet need. Nonetheless, a diagnostic approach that captures early skin ulceration and treatments that restore vascular and immune homeostasis is critical for effective systemic sclerosis (SSc) vasculopathy management.
Keywords: Capillaroscopy; Skin ulcer; Systemic sclerosis; Vasculopathy.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest None declared.
Figures




Similar articles
-
Treatment of Vascular Complications in Systemic Sclerosis: What Is the Best Approach to Diagnosis and Management of Renal Crisis and Digital Ulcers?Rheum Dis Clin North Am. 2023 May;49(2):263-277. doi: 10.1016/j.rdc.2023.01.004. Rheum Dis Clin North Am. 2023. PMID: 37028834 Review.
-
Frontiers in translational systemic sclerosis research: A focus on the unmet 'cutaneous' clinical needs (Viewpoint).Exp Dermatol. 2020 Dec;29(12):1144-1153. doi: 10.1111/exd.14179. Exp Dermatol. 2020. PMID: 32840924 Review.
-
Diagnosis and management of systemic sclerosis-related calcinosis.Expert Rev Clin Immunol. 2023 Jan;19(1):45-54. doi: 10.1080/1744666X.2023.2144835. Epub 2022 Nov 23. Expert Rev Clin Immunol. 2023. PMID: 36333952 Review.
-
[Pathogenic mechanisms in systemic sclerosis and their therapeutical consequences. Part 2: treatment].Rev Med Suisse. 2006 Apr 19;2(62):1058, 1060-6. Rev Med Suisse. 2006. PMID: 16711151 Review. French.
-
Raynaud's phenomenon and digital ulcers: advances in evaluation and management.Curr Opin Rheumatol. 2021 Nov 1;33(6):453-462. doi: 10.1097/BOR.0000000000000826. Curr Opin Rheumatol. 2021. PMID: 34420003 Review.
Cited by
-
Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis.J Inflamm Res. 2023 Oct 17;16:4633-4660. doi: 10.2147/JIR.S379815. eCollection 2023. J Inflamm Res. 2023. PMID: 37868834 Free PMC article. Review.
-
Peripheral Macrovascular Involvement in Systemic Sclerosis: A Cohort Study by Color and Spectral Doppler Ultrasonography.Life (Basel). 2023 Feb 10;13(2):487. doi: 10.3390/life13020487. Life (Basel). 2023. PMID: 36836844 Free PMC article.
-
Biomarkers in Systemic Sclerosis: An Overview.Curr Issues Mol Biol. 2023 Sep 25;45(10):7775-7802. doi: 10.3390/cimb45100490. Curr Issues Mol Biol. 2023. PMID: 37886934 Free PMC article. Review.
-
mTG-Gelatin phantoms as standardized testbeds for skin biomechanical measurements with Myoton.J Mech Behav Biomed Mater. 2024 Oct;158:106651. doi: 10.1016/j.jmbbm.2024.106651. Epub 2024 Jul 2. J Mech Behav Biomed Mater. 2024. PMID: 39059120
-
Mesenchymal stem cell-derived extracellular vesicles in systemic sclerosis: role and therapeutic directions.Front Cell Dev Biol. 2024 Oct 17;12:1492821. doi: 10.3389/fcell.2024.1492821. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39483335 Free PMC article. Review.
References
-
- Tolosa-Vilella C, Morera-Morales ML, Simeón-Aznar CP, et al. Digital ulcers and cutaneous subsets of systemic sclerosis: clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. Semin Arthritis Rheum 2016;46:200–8. 10.1016/j.semarthrit.2016.04.007. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical